CRISPR Therapeutics AG (CRSP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350M 700M 1.1B Q4 '15: 247K Q1 '16: 476K Q2 '16: 795K Q3 '16: 1.5M Q4 '16: 2.3M Q1 '17: 2.7M Q2 '17: 3.6M Q3 '17: 2.4M Q4 '17: 32.3M Q1 '18: 1.4M Q2 '18: 1.1M Q3 '18: 563K Q4 '18: 115K Q1 '19: 328K Q2 '19: 318K Q3 '19: 211.9M Q4 '19: 77M Q1 '20: 157K Q2 '20: 44K Q3 '20: 148K Q4 '20: 370K Q1 '21: 539K Q2 '21: 900.7M Q3 '21: 824K Q4 '21: 12.9M Q1 '22: 940K Q2 '22: 158K Q3 '22: 94K Q4 '22: 6K Q1 '23: 100M Q2 '23: 70M Q3 '23: 0 Q4 '23: 201.2M Q1 '24: 504K Q2 '24: 517K Q3 '24: 602K Q4 '24: 35.7M Q1 '25: 865K Q2 '25: 892K Q3 '25: 889K Q4 '25: 864K Q1 '26: 1.5M Q2 '26: 10.2M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-300M 0 300M 600M 900M Q1 '15: -3.7M Q2 '15: -3.6M Q3 '15: -6.2M Q4 '15: -12.2M Q1 '16: -11.7M Q2 '16: -16.6M Q3 '16: -14.6M Q4 '16: -25.3M Q1 '17: -20.7M Q2 '17: -21.3M Q3 '17: -23.6M Q4 '17: 972K Q1 '18: -27M Q2 '18: -37.3M Q3 '18: -49.4M Q4 '18: -45.2M Q1 '19: -48.4M Q2 '19: -55M Q3 '19: 139.2M Q4 '19: 11M Q1 '20: -73.6M Q2 '20: -80.7M Q3 '20: -92.4M Q4 '20: -107.8M Q1 '21: -114.5M Q2 '21: 762.6M Q3 '21: -128.8M Q4 '21: -145.7M Q1 '22: -176M Q2 '22: -183.3M Q3 '22: -182.4M Q4 '22: -131.5M Q1 '23: -64.5M Q2 '23: -95.2M Q3 '23: -132.4M Q4 '23: 69.6M Q1 '24: -140.6M Q2 '24: -151.3M Q3 '24: -110.1M Q4 '24: -64.6M Q1 '25: -148.4M Q2 '25: -229.3M Q3 '25: -132.1M Q4 '25: -154.8M Q1 '26: -130.2M Q2 '26: -117.3M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income Quarterly

-300M 0 300M 600M 900M Q1 '15: -3.2M Q2 '15: -3.6M Q3 '15: -6.4M Q4 '15: -12.3M Q1 '16: -8.4M Q2 '16: -17.2M Q3 '16: -14.7M Q4 '16: 17.1M Q1 '17: -21.5M Q2 '17: -22.3M Q3 '17: -24.7M Q4 '17: 140K Q1 '18: -28.3M Q2 '18: -38.4M Q3 '18: -50.7M Q4 '18: -47.6M Q1 '19: -48.4M Q2 '19: -53.7M Q3 '19: 138.4M Q4 '19: 30.5M Q1 '20: -69.7M Q2 '20: -79.7M Q3 '20: -92.4M Q4 '20: -107M Q1 '21: -113.2M Q2 '21: 759.2M Q3 '21: -127.2M Q4 '21: -141.2M Q1 '22: -179.2M Q2 '22: -185.8M Q3 '22: -174.5M Q4 '22: -110.6M Q1 '23: -53.1M Q2 '23: -77.7M Q3 '23: -112.2M Q4 '23: 89.3M Q1 '24: -116.6M Q2 '24: -126.4M Q3 '24: -85.9M Q4 '24: -37.3M Q1 '25: -136M Q2 '25: -208.5M Q3 '25: -106.4M Q4 '25: -130.6M Q1 '26: -122.9M Q2 '26: -91.2M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-300M 0 300M 600M 900M Q4 '15: 69M Q1 '16: -10M Q2 '16: -13.6M Q3 '16: -12.3M Q4 '16: -19.4M Q1 '17: -23.4M Q2 '17: -16M Q3 '17: -15.9M Q4 '17: -14.8M Q1 '18: -22.7M Q2 '18: -25.2M Q3 '18: -20M Q4 '18: -28.4M Q1 '19: -43.7M Q2 '19: -36.4M Q3 '19: 133.4M Q4 '19: 3.4M Q1 '20: -52.2M Q2 '20: -29.3M Q3 '20: -75.7M Q4 '20: -81.2M Q1 '21: -100.7M Q2 '21: 807M Q3 '21: -81.3M Q4 '21: -86M Q1 '22: -135.2M Q2 '22: -142M Q3 '22: -105.2M Q4 '22: -113.3M Q1 '23: 8.8M Q2 '23: -133.2M Q3 '23: -39.9M Q4 '23: -96.1M Q1 '24: 109.8M Q2 '24: -95.6M Q3 '24: -106.9M Q4 '24: -50M Q1 '25: -53.9M Q2 '25: -113.9M Q3 '25: -84.6M Q4 '25: -92.6M Q1 '26: -108.9M Q2 '26: -83.5M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow Quarterly

-300M 0 300M 600M 900M Q4 '15: 68.5M Q1 '16: -10.2M Q2 '16: -14.7M Q3 '16: -13.8M Q4 '16: -19.6M Q1 '17: -26.7M Q2 '17: -17.3M Q3 '17: -18.9M Q4 '17: -15M Q1 '18: -23.2M Q2 '18: -25.7M Q3 '18: -20.7M Q4 '18: -29.4M Q1 '19: -44.8M Q2 '19: -38.6M Q3 '19: 131M Q4 '19: 2.4M Q1 '20: -55.2M Q2 '20: -32.9M Q3 '20: -81.2M Q4 '20: -87.5M Q1 '21: -107.7M Q2 '21: 778.6M Q3 '21: -118.4M Q4 '21: -95.2M Q1 '22: -150.6M Q2 '22: -151.6M Q3 '22: -111.2M Q4 '22: -119.5M Q1 '23: 5.7M Q2 '23: -136.8M Q3 '23: -42M Q4 '23: -96.8M Q1 '24: 109M Q2 '24: -96.3M Q3 '24: -107.1M Q4 '24: -50.3M Q1 '25: -54.2M Q2 '25: -114M Q3 '25: -84.7M Q4 '25: -93.1M Q1 '26: -109.4M Q2 '26: -84.1M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '16: 5.5M Q2 '16: 5.4M Q3 '16: 5.3M Q4 '16: 35M Q1 '17: 39.7M Q2 '17: 39.9M Q3 '17: 40.1M Q4 '17: 41.6M Q1 '18: 45.9M Q2 '18: 46.8M Q3 '18: 47.4M Q4 '18: 51.7M Q1 '19: 52.1M Q2 '19: 53.2M Q3 '19: 57.6M Q4 '19: 60.2M Q1 '20: 60.8M Q2 '20: 61.4M Q3 '20: 70.1M Q4 '20: 71.3M Q1 '21: 75M Q2 '21: 80.4M Q3 '21: 76.3M Q1 '22: 77.1M Q2 '22: 77.5M Q3 '22: 78M Q1 '23: 78.7M Q2 '23: 79.1M Q3 '23: 79.4M Q1 '24: 81.8M Q2 '24: 84.9M Q3 '24: 85.2M Q1 '25: 85.9M Q2 '25: 87.1M Q3 '25: 91.3M Q1 '26: 96.1M Q2 '26: 96.5M Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '15: -5.08 Q1 '16: -5.70 Q2 '16: -8.05 Q3 '16: -9.67 Q4 '16: -7.05 Q1 '17: -6.06 Q2 '17: -3.47 Q3 '17: -1.32 Q4 '17: -1.72 Q1 '18: -1.80 Q2 '18: -2.06 Q3 '18: -2.51 Q4 '18: -3.43 Q1 '19: -3.74 Q2 '19: -3.93 Q3 '19: -0.46 Q4 '19: 0.97 Q1 '20: 0.75 Q2 '20: 0.46 Q3 '20: -3.26 Q4 '20: -5.27 Q1 '21: -5.63 Q2 '21: 5.11 Q3 '21: 4.76 Q4 '21: 4.70 Q1 '22: 3.89 Q2 '22: -7.95 Q3 '22: -8.52 Q4 '22: -8.36 Q1 '23: -6.71 Q2 '23: -5.29 Q3 '23: -4.46 Q4 '23: -1.94 Q1 '24: -2.70 Q2 '24: -3.21 Q3 '24: -2.81 Q4 '24: -4.35 Q1 '25: -4.50 Q2 '25: -5.41 Q3 '25: -5.57 Q4 '25: -6.50 Q1 '26: -6.20 Q2 '26: -4.74 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.